Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Research Report 2025

Summary


Duchenne muscular dystrophy, sometimes shortened to DMD or just Duchenne, is a rare genetic disease. It predominantly affects males, but, in rare cases, can also affect females. Duchenne causes the muscles in the body to become weak and damaged over time and is eventually fatal. The genetic change that causes Duchenne—a mutation in the DMD gene—happens before birth and can be inherited, or new mutations in the gene can occur spontaneously. Muscle weakness becomes increasingly noticeable between the ages of 3 and 5, and most patients use a wheelchair by the time they are 12. During adolescence, heart and breathing muscles weaken, leading to serious, life-threatening complications.

According to APO Research, The global Duchenne Muscular Dystrophy (DMD) Therapeutics market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Duchenne Muscular Dystrophy (DMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Duchenne Muscular Dystrophy (DMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Duchenne Muscular Dystrophy (DMD) Therapeutics is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Duchenne Muscular Dystrophy (DMD) Therapeutics include Sarepta Therapeutics, PTC Therapeutics, Pfizer, Bristol-Myers Squibb, Italfarmaco and Santhera Pharmaceuticals, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Duchenne Muscular Dystrophy (DMD) Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Duchenne Muscular Dystrophy (DMD) Therapeutics.
The Duchenne Muscular Dystrophy (DMD) Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Duchenne Muscular Dystrophy (DMD) Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Company

Sarepta Therapeutics
PTC Therapeutics
Pfizer
Bristol-Myers Squibb
Italfarmaco
Santhera Pharmaceuticals
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Type

Exondys
Emflaza
Translarna
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals
Clinics
Home Care
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Application

Hospitals
Clinics
Home Care
Duchenne Muscular Dystrophy (DMD) Therapeutics Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Duchenne Muscular Dystrophy (DMD) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Duchenne Muscular Dystrophy (DMD) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Duchenne Muscular Dystrophy (DMD) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Duchenne Muscular Dystrophy (DMD) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics by Type
2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
2.2.2 Exondys
2.2.3 Emflaza
2.2.4 Translarna
2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics by Application
2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.3.2 Hospitals
2.3.3 Clinics
2.3.4 Home Care
2.4 Assumptions and Limitations
3 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Type
3.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Type (2020-2025)
3.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Type (2026-2031)
4 Duchenne Muscular Dystrophy (DMD) Therapeutics Breakdown Data by Application
4.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Application (2020-2025)
4.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Application (2026-2031)
5 Global Growth Trends
5.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Perspective (2020-2031)
5.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Growth Trends by Region
5.2.1 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Region: 2020 VS 2024 VS 2031
5.2.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Historic Market Size by Region (2020-2025)
5.2.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Forecasted Market Size by Region (2026-2031)
5.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Dynamics
5.3.1 Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Trends
5.3.2 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Drivers
5.3.3 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Challenges
5.3.4 Duchenne Muscular Dystrophy (DMD) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
6.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue
6.1.1 Global Top Duchenne Muscular Dystrophy (DMD) Therapeutics Players by Revenue (2020-2025)
6.1.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Revenue Market Share by Players (2020-2025)
6.2 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
6.3 Global Key Players of Duchenne Muscular Dystrophy (DMD) Therapeutics Head Office and Area Served
6.4 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Players, Product Type & Application
6.5 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Manufacturers Established Date
6.6 Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market CR5 and HHI
6.7 Global Players Mergers & Acquisition
7 North America
7.1 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
7.2 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
7.4 North America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
7.5 United States
7.5 United States
7.6 Canada
7.7 Mexico
8 Europe
8.1 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
8.2 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
8.3 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
8.4 Europe Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
8.5 Germany
8.6 France
8.7 U.K.
8.8 Italy
8.9 Spain
8.10 Russia
8.11 Netherlands
8.12 Nordic Countries
9 Asia-Pacific
9.1 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
9.2 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
9.4 Asia-Pacific Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
9.5 China
9.6 Japan
9.7 South Korea
9.8 India
9.9 Australia
9.10 China Taiwan
9.11 Southeast Asia
10 South America
10.1 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
10.2 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
10.4 South America Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
10.5 Brazil
10.6 Argentina
10.7 Chile
10.8 Colombia
10.9 Peru
11 Middle East & Africa
11.1 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size (2020-2031)
11.2 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Growth Rate by Country: 2020 VS 2024 VS 2031
11.3 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2020-2025)
11.4 Middle East & Africa Duchenne Muscular Dystrophy (DMD) Therapeutics Market Size by Country (2026-2031)
11.5 Saudi Arabia
11.6 Israel
11.7 United Arab Emirates
11.8 Turkey
11.9 Iran
11.10 Egypt
12 Players Profiled
12.1 Sarepta Therapeutics
12.1.1 Sarepta Therapeutics Company Information
12.1.2 Sarepta Therapeutics Business Overview
12.1.3 Sarepta Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.1.4 Sarepta Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.1.5 Sarepta Therapeutics Recent Developments
12.2 PTC Therapeutics
12.2.1 PTC Therapeutics Company Information
12.2.2 PTC Therapeutics Business Overview
12.2.3 PTC Therapeutics Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.2.4 PTC Therapeutics Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.2.5 PTC Therapeutics Recent Developments
12.3 Pfizer
12.3.1 Pfizer Company Information
12.3.2 Pfizer Business Overview
12.3.3 Pfizer Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.3.4 Pfizer Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.3.5 Pfizer Recent Developments
12.4 Bristol-Myers Squibb
12.4.1 Bristol-Myers Squibb Company Information
12.4.2 Bristol-Myers Squibb Business Overview
12.4.3 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.4.4 Bristol-Myers Squibb Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.4.5 Bristol-Myers Squibb Recent Developments
12.5 Italfarmaco
12.5.1 Italfarmaco Company Information
12.5.2 Italfarmaco Business Overview
12.5.3 Italfarmaco Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.5.4 Italfarmaco Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.5.5 Italfarmaco Recent Developments
12.6 Santhera Pharmaceuticals
12.6.1 Santhera Pharmaceuticals Company Information
12.6.2 Santhera Pharmaceuticals Business Overview
12.6.3 Santhera Pharmaceuticals Revenue in Duchenne Muscular Dystrophy (DMD) Therapeutics Business (2020-2025)
12.6.4 Santhera Pharmaceuticals Duchenne Muscular Dystrophy (DMD) Therapeutics Product Portfolio
12.6.5 Santhera Pharmaceuticals Recent Developments
13 Report Conclusion
14 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings